



Companies to Watch


The \$1 trillion opportunity: Rethinking investment in women's health

Webinar


October, 2025

Women's health


Examples of the unbalance of research funding vs. disease burden in women



Losing out across the board



How more funding would help



Source: The funding gender gap (Kerri Smith) Nature | Vol 617 | 4 May 2023 <https://www.nature.com/immersive/d41586-023-01475-2/index.html>

Biopharma pipelines of women's health products and deals for female infertility


1,028
companies working on
2,161
women's health products



Biopharma companies with 11 or more products in development for women's health:

- Merck KGaA
- AstraZeneca
- GSK
- Ferring
- Novartis
- Roche
- Biocad
- Italfarmaco
- Bayer
- Biontech
- Boehringer Ingelheim
- H. Lundbeck
- Beigene
- Abbvie
- Daré
- Incyte
- Omeros
- Organon
- Protheragen
- Regeneron


Biopharma pipelines of women's health products



*Represents the proportion of products coming from North American and European companies with one, two, three, four, five or six-plus women's health therapeutics in their pipelines

Female Infertility

Annual Deal Volume Jan 2025 - Dec 2025



SOURCE: [The data on women's health | BioWorld](#)

SOURCE: Cortellis Competitive Intelligence

Success of endometriosis drugs across development phases

Endometriosis

Historical Overview - Success Rate

Phase	Success Rate
Phase 1	64.29%
Phase 2	47.06%
Phase 3	75%
Pre Registration	100%

SOURCE: Cortellis Competitive Intelligence - Disease Timeline & Success Rate

Benchmark data for success rates

Phase transitions	Success rates (2002-2020)
Phase 1 --> Phase 2	57%
Phase 2 --> Phase 3	28%
Phase 3 --> Pre-registration	69%
Pre-registration --> Registration	94%

Source: 2023 CMR International Pharmaceutical R&D Factbook

Overview

Despite representing half the global population, women have long been **excluded from equitable health research and funding**. Conditions that disproportionately affect women—like migraines, cognitive disorders, and maternal health—remain underfunded, while clinical guidelines often overlook female-specific risk factors. Yet momentum is building.

Landmark studies, targeted funding initiatives and a growing recognition of the sex health divide **are reshaping the landscape**.



Why women's health remains underfunded despite its \$1tn economic potential?



How gender bias in clinical research impacts diagnosis and treatment?



Key funding shifts fueling innovation in underserved areas



Strategies for continuing the momentum globally

Panelists



Michael Ward

Head of Thought Leadership

Life Sciences and Healthcare, Clarivate

michael.ward@clarivate.com



Agnès Arbat M.D.

CEO, CMO and co-founder

Oxolife



Colleen Acosta PhD

CEO and co-founder

Freya Biosciences



Anette Breindl PhD

Managing Editor

Clarivate



Hakan Goker PhD

Managing Director

M Ventures

How can Clarivate help?

Through transformative intelligence, we empower you to anticipate and address healthcare's biggest challenges in an ever-evolving world.



Cortellis Competitive Intelligence

Understand the complete drug pipeline

Monitor the competition in your therapeutic area of interest with pipeline intelligence covering the entire development lifecycle, from discovery and preclinical through product launch.

Accurately forecast pipeline movements and timelines

Predict the likelihood and timing of competing drug launches with the Drug Timeline & Success Rates machine learning-based predictive analytics.

Validate your investments

Inform confident portfolio and business development decisions using expansive coverage of clinical, deals, regulatory, and patent insights tied to each drug and company.



BioWorld

Stay ahead with real-time biopharma intelligence

Access data and developments delivered in real time, offering both granular detail and the big-picture view of the life sciences landscape.

Gain context that drives action

BioWorld connects the dots—delivering historic context, expert analysis, and the “what’s-in-it-for-me” perspective to turn breaking news into strategic insight.

Rely on trusted, original reporting

Go straight to the source with exclusive interviews, regulatory updates, deal trends, and analytical reports that inform smarter decisions from discovery through launch.



Think forward

About Clarivate

Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.

© 2025 Clarivate. All rights reserved

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.